Tissue factor pathway inhibitor-2 (TFPI-2) recognizes the complement and kininogen binding protein gCIqR/p33 (gCIqR): Implications for vascular inflammation

Thrombosis and Haemostasis

Volumn 92, Issue 4, 2004, Pages 811-819

  Peerschke, Ellinor I B ^a,d   Petrovan, Ramona J ^b   Ghebrehiwet, Berhane ^c   Ruf, Wolfram ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Atherosclerosis; Fibrinolysis inhibitors; Proteases inhibitors; Proteolysis pericellular; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

AMINO ACID; BINDING PROTEIN; COMPLEMENT; HIGH MOLECULAR WEIGHT KININOGEN; KININOGEN; PLACENTA PROTEIN 5; PLASMIN; PROTEIN ANTIBODY; PROTEINASE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING ASSAY; DATA ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; GENE DELETION; IMMUNOPRECIPITATION; INFLAMMATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; STATISTICAL SIGNIFICANCE; SURFACE PLASMON RESONANCE; VASCULAR DISEASE;

ANTIGENS, CD44; CARRIER PROTEINS; COMPLEMENT C1Q; ENDOTHELIUM, VASCULAR; GLYCOPROTEINS; HUMANS; INFLAMMATION; KALLIKREINS; KININOGEN, HIGH-MOLECULAR-WEIGHT; MITOCHONDRIAL PROTEINS; PLASMIN; PROTEIN BINDING;

EID: 6344292453     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-03-0188     Document Type: Article

References (49)

1. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol 1994; 89 (Suppl): 59-70.
2. Nagase H, Woessner JH. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
3. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-8.
4. Libby P, Lee RT. Matrix matters. Circulation 2000; 102: 1874-6.
5. Petersen LC, Sprecher CA, Foster DC, et al. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996; 35: 266-72.
6. Rao CN, Reddy P, Lie Y et al. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single gene-products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys 1996; 335: 82-92.
7. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001; 107: 1117-26.
8. Rice A, Chard T. A method for the purification of placental protein 5 (PP5) from placental extracts. Clin Chim Acta 1983; 131: 289-94.
9. Udagawa K, Miyagi Y, Hirahara F, et al. Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 1998; 19: 217-23.
10. Udagawa K, Yasumitsu H, Esaki M, et al. Subcellular localization of PP5 TFPI-2 in human placenta: possible role of PP5 TFPI-2 as an anticoagulant on the surface of syncytiotrophoblasts. Placenta 2002; 23: 145-53.
11. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1994; 71: 275-9.
12. Miyagi Y, Koshikawa N, Yasumitsu H, et al. cDNA cloning and mRNA expression of a serine proteinase secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor. J Biochem 1994; 116: 939-42.
13. Crawley JTB, Goulding DA, Ferreira V, et al. Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2002; 22: 218-24.
14. Peerschke EIB, Minta JO, Zhou SZ, et al. Expression of gC1qR/p33 and its major ligands in human atherosclerotic lesions. Molec Immunol 2004; 41: 759-66.
15. Ghebrehiwet B, Lim BL, Peerschke EIB, et al. Isolation, cDNA cloning, and overexpression of a 33-kDa cell surface glycoprotein that binds to the globular 'heads' of C1q. J Exp Med 1994;179: 1809-21.
16. Deb TB, Datta K. Molecular cloning of human fibroblast hyaluronic acid binding protein confirms its identity with P-32, a protein copurified with splicing factor SF2. J Biol Chem 1996; 269: 2206-12.
17. Ghebrehiwet B, Lim B-L, Kumar R, et al. gC1qR/p33: a member of a new class of multifunctional and multicompartmental cellular proteins is involved in inflammation and infection. Immunol Rev 2001; 180: 65-77.
18. Ghebrehiwet B, Jesty J, Peerschke EIB. gC1qR/p33: Structure-function predictions from the crystal structure. Immunobiology 2002; 205: 421-32.
19. Peerschke EIB, Ghebrehiwet B. Human blood platelet gC1qR. Immunol Rev 2001; 180: 56-64.
20. Joseph K, Ghebrehiwet B, Peerschke EIB, et al. Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor which binds to the globular 'heads' of C1q (gC1q-R). Proc Natl Acad Sci USA 1996; 93: 8552-7.
21. Shibayama Y, Joseph K, Ghebrehiwet B, et al. Identification of gC1qR, the endothelial cell receptor for the globular heads of C1q as a naturally occurring initiator of the intrinsic blood coagulation and kinin-generating pathway. Blood 1996; 88: 524a.
22. Nguyen T, Ghebrehiwet B, Peerschke EIB. Staphylococcus aureus Protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcus interactions with platelets. Infect Immun 2000; 68: 2061-8.
23. Braun L, Ghebrehiwet B, Cossart P. gC1qR/p33, a C1q binding protein, is a novel receptor for Listeria monocytogenes. EMBO J 2000; 19: 1458-66.
24. Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, et al. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Immunol 2000; 106: 1239-49.
25. Luo Y, Yu H, Peterlin PM. Cellular protein modulates effects of human immunodeficiency virus type 1 Tat transactivator and the general transcription factor TFPIIB with the cellular protein TAP. J Virol 1995; 69: 3017-23.
26. Rozanov DV, Ghebrehiwet B, Postnova TI, et al. The hemopexin-like C-terminal domain of membrane type matrix metalloproteinase regulates proteolysis of a multifunctional protein, gC1qR. J Biol Chem 2002; 277: 9318-25.
27. Fischer EG, Riewald M, Huang HY, et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999; 104: 1213-21.
28. Ott I, Miyagi Y, Miyazaki K, et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-82.
29. Sprecher CA, Kisiel W, Mathews S, et al. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-7.
30. Wun TC, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
31. Stone MJ, Ruf W, Miles DJ, et al. Recombinant soluble human Tissue Factor secreted by Saccaromyces cerevisiae and refolded from Escherichia coli inclusion bodies: Glycosylation of mutants, activity, and physical characterization. Biochem J 1995; 310: 605-14.
32. Rao CN, Reddy P, Reeder DJ, et al. Prokaryotic expression, purification, and reconstitution of biological activities (antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. Biochem Biophys Res Commun 2000; 276: 1286-94.
33. Ghebrehiwet B, Lu PD, Zhang W, et al. Identification of functional domains on gC1qR, a cell surface protein which binds to the globular "heads" of C1q, using monoclonal antibodies and synthetic peptides. Hybridoma 1996; 15: 333-42.
34. Menabawey M, Silman R, Rice A, et al. Dramatic increase of placental protein 5 levels following injection of small doses of heparin. Brit J Obstet Gynaecol 1985; 92: 207-10.
35. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
36. Kario K, Matsuo T, Yamada T, et al. Increased tissue factor pathway inhibitor levels in uremic patients on regular hemodialysis. Thromb Haemost 1994; 71: 275-9.
37. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
38. Guo WX, Ghebrehiwet B, Weksler B, et al. Upregulation of endothelial cell binding proteins/receptors for complement component C1q by inflammatory cytokines. J Lab Clin Med 1999; 133: 541-50.
39. Jiang J, Zhang Y, Krainer AR, et al. Crystal structure of p32, a doughnut-shaped acidic mitochondrial matrix protein. Proc Natl Acad Sci USA 1999; 96: 3572-7.
40. Blindt R, Vogt F, Lamby D, et al. Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells. J Vasc Res 2002; 39: 340-52.
41. Jin M, Udagawa K, Miyagi E, et al. Expression of serine proteinase inhibitor PPG-TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 2001; 83: 325-33.
42. Konduri SD, Rao CN, Chandrasekar N, et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 2001; 20: 6938-45.
43. Konduri SD, Tasiou A, Chandrasekar N, et al. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000; 18: 303-8.
44. Neaud V, Hisaka T, Monvoisin A, et al. Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J Biol Chem 2000; 275: 35565-9.
45. Mahdi F, Shariat-Madar Z, Todd RF III, et al. Expression and colocalization of cytokeratin I and urokinase plasminogen activator receptor on endothelial cells. Blood 2001; 97: 2342-50.
46. Peerschke EIB, Murphy TK, Ghebrehiwet B. Activation-dependent surface expression of gC1qR/p33 on human blood platelets. Thromb Haemost 2003; 89: 331-9.
47. Mahdi F, Madar ZS, Figueroa CD, et al. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585-96.
48. Chen A, Gaddipati S, Hong Y, et al. Human T cells express specific binding sites for C1q. Role in T cell activation and proliferation. J Immunol 1994; 153: 1430-40.
49. Chad HS, Schmidt AE, Bajaj SP, et al. Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2. J Biol Chem 2004; 279: 17500-7.